Initiating Coverage · Nasdaq: GH · Health Care — Precision Oncology · May 30, 2026
Guardant Health
Liquid Biopsy & Cancer Screening Platform
▲ Buy
PT $160
Mkt Cap $17.7B
SmartScore 9/10
$129.69
Current Price · May 29, 2026
+208% trailing 12 months
⚡ Next earnings: July 30, 2026
Investment Thesis
Guardant Health is transitioning from a pure oncology diagnostics company into a multi-product liquid biopsy platform with a once-in-a-decade commercial opportunity in Shield — the first and only FDA-approved blood-based colorectal cancer screening test with Medicare coverage. Revenue grew 48% YoY in Q1 2026 to $302M and we model a path to $1.35B in FY2026E. While the company remains deeply loss-making, operating leverage is compressing rapidly (operating margin improved from -55% to -40% YoY) and the $1.1B cash position provides adequate runway. The Shield MCD multi-cancer detection expansion, ADLT reimbursement potential, and biopharma revenue diversification underpin our 12-month price target of $160, implying ~23% upside from current levels.
52-Week Range
$39.70–$133.97
Near 52-wk high
Q1 2026 Revenue
$301.7M
+48% YoY
Gross Margin (Q1)
65.2%
+1.9pts YoY
EV / 2026E Revenue
14.5x
vs NTRA ~21x
Analyst Consensus
Strong Buy
15B · 1H · 0S
Cash & Investments
$1.2B
~2.5yr runway
Income Statement Forecast ($M) · E = Estimate
| FY2023A | FY2024A | FY2025A | FY2026E | FY2027E | FY2028E |
|---|
| Revenue |
| Precision oncology | $468 | $600 | $752 | $906 | $1,087 | $1,261 |
| Development services | $96 | $139 | $230 | $441 | $573 | $700 |
| Total Revenue | $564 | $739 | $982 | $1,347 | $1,660 | $1,961 |
| YoY Growth | +26% | +31% | +33% | +37% | +23% | +18% |
| Profitability |
| Gross Profit | $337 | $449 | $633 | $890 | $1,129 | $1,373 |
| Gross Margin | 59.7% | 60.8% | 64.5% | 66.1% | 68.0% | 70.0% |
| R&D | $367 | $348 | $364 | $390 | $415 | $440 |
| Sales & Marketing | $372 | $424 | $580 | $700 | $747 | $745 |
| Operating Income | -$565 | -$444 | -$436 | -$375 | -$215 | +$0 |
| Operating Margin | -100% | -60% | -44% | -28% | -13% | ~0% |
| Net Income | -$479 | -$436 | -$416 | -$350 | -$185 | +$30 |
| EPS (Diluted) | -$4.28 | -$3.56 | -$3.32 | -$2.65 | -$1.35 | +$0.21 |
Balance Sheet & Cash Flow Forecast ($M)
| FY2024A | FY2025A | FY2026E | FY2027E | FY2028E |
|---|
| Balance Sheet |
| Cash & Investments | $840 | $1,202 | $890 | $730 | $800 |
| Total Assets | $1,486 | $2,014 | $2,100 | $2,050 | $2,100 |
| Total Debt | $1,336 | $1,682 | $1,700 | $1,700 | $1,500 |
| Total Equity | -$140 | -$99 | -$200 | -$250 | +$30 |
| Cash Flow |
| Operating Cash Flow | -$240 | -$185 | -$270 | -$140 | +$60 |
| Capital Expenditures | -$35 | -$48 | -$60 | -$65 | -$70 |
| Free Cash Flow | -$275 | -$233 | -$330 | -$205 | ~-$10 |
| FCF Margin | -37% | -24% | -24% | -12% | ~0% |
Valuation Framework
Base Case Price Target
$160
17.5x EV/2026E revenue · +23% upside
DCF Range (10yr, 12% WACC, 3% terminal)
$145–$175
Midpoint $160 · Revenue CAGR tapering 37%→18% · GM to 72%
| Metric | GH Current | GH @ PT $160 | NTRA (Peer) |
|---|
| Market Cap | $17.7B | $21.8B | $30.6B |
| Enterprise Value (est.) | ~$19.5B | ~$23.6B | ~$29.5B |
| EV / 2026E Revenue | 14.5x | 17.5x | ~21x |
| EV / 2027E Revenue | 11.7x | 14.2x | ~16x |
| Revenue Growth (2026E) | +37% | — | +28% |
| Gross Margin (2026E) | 66% | — | ~70% |
| Consensus PT | $131.73 | — | $258.10 |
12-Month Price Target Scenarios
Bull Case
$210
+62% upside
ADLT designation secured ($900+ reimbursement). Commercial payer adoption accelerates. MCD Breakthrough Device fast-tracked. Revenue $1.6B in FY2026E. Multiple re-rates to 22x fwd revenue.
Base Case
$160
+23% upside
Shield steady ramp. Medicare volumes +60%+ YoY. Commercial coverage expands to ~40%. Revenue $1.35B in FY2026E. Operating margin improves to -28%. Multiple holds at ~17.5x.
Bear Case
$85
-34% downside
ACS guidelines dampen adoption. Commercial payer coverage stalls. S&M fails to convert. Revenue growth decelerates to 20%. Capital raise required, diluting ~15%. Multiple compresses to 10x.
Key Catalysts — Next 12 Months
Jul 30, 2026
Q2 2026 Earnings
Shield volume guidance and payer coverage update will be the primary focus. We model $340M revenue / -26% op margin. A beat + raise scenario could push the stock to $150+.
H2 2026
ADLT Designation Decision
If granted, Shield reimbursement could jump from ~$500 to $900+, materially improving unit economics. The single biggest financial catalyst in the next 12 months.
2026–2027
Commercial Payer Coverage Milestones
Each major commercial insurer (UnitedHealth, Aetna, BCBS) adding Shield to formulary unlocks millions of eligible lives. Current commercial coverage ~25–30%.
2026
Shield MCD Data Readout / FDA Pathway
MCD has Breakthrough Device designation. Positive clinical data or FDA feedback on an approval timeline could meaningfully expand the TAM narrative.
Ongoing
NCCN Guideline Expansion & Oncology Volume
Guardant360 CDx label expansions and Guardant Reveal MRD adoption continue to compound the oncology base. Each approval broadens the biopharma partnership pipeline.
Risk Register
Payer Coverage Execution Risk
ACS guidelines categorize blood tests as a secondary screening option — giving payers grounds to resist broad coverage. A slow commercial rollout is the single biggest threat to the bull thesis.
Cash Burn & Financing Risk
We model -$330M FCF in FY2026E and cash declining to ~$890M. At current burn rates, GH has 2.5–3 years of runway. The $1.7B debt load further constrains flexibility.
S&M Leverage Risk
S&M spend jumped 62% YoY in Q1 2026 to $169M. If this doesn't convert to proportional volume growth, the operating leverage story breaks down. Key watchpoint at Q2 earnings.
Competitive Response
Exact Sciences, Grail, and Illumina-backed ventures pursue liquid biopsy and MCD. A better-funded competitor securing earlier commercial payer contracts could limit GH's first-mover advantage.
Negative Equity & Debt Covenant Risk
Total stockholders' equity is negative (-$99M FY2025). Lenders imposing covenants triggered by sustained negative equity could restrict GH's $1.7B debt stack.
CMS Reimbursement Policy Changes
CMS could revisit reimbursement rates in future Physician Fee Schedule updates. Any downward revision to the ~$500 Medicare rate would compress economics on the largest payer segment.
Sentiment & Technical Indicators
Analyst Consensus
Strong Buy
15B · 1H · 0S
Best Analysts Only
Strong Buy
7B · 0H · 0S · PT $131
SmartScore
9 / 10
Outperform tier
Hedge Fund Signal
Net Sell
Score: 0.08 — light HF positioning
Insider Activity
Net Sell
Multiple Form 144s filed May '26
News Sentiment
Bullish
Score: 0.89 / 1.0
| Technical Indicator | Value | Signal | Interpretation |
|---|
| RSI (14) — Weekly | 72.4 | Sell | Overbought — momentum stretched, pullback risk near-term |
| Stochastics %K | 90.3 | Sell | Extremely overbought — caution on new entries |
| All MAs (5–200, SMA + EMA) | All above | Strong Buy | Price above all moving averages — trend intact |
| Classic Pivot R1 / R2 | $129 / $139 | Neutral | At R1 resistance — needs to break $139 to retest highs |
| Classic Support S1 | $101.8 | Buy Zone | Key support on any pullback — preferred entry level |
Analyst Bottom Line
Summary & Key Conviction Points
The core debate on GH: is Shield a $1B+ revenue product or a niche diagnostics tool? We believe it's the former. Q1 2026 data — 48% revenue growth, improving gross margins, compressing operating losses — is the early proof. The stock has re-rated +208% in a year, but the ADLT designation decision and commercial payer coverage milestones are underappreciated catalysts not yet in the Street consensus PT of $131.
GH needs ~$1.8B in revenue at ~70% gross margins to generate meaningful EBITDA — achievable in FY2027–FY2028 at current growth trajectory. At $130, you're paying 14.5x FY2026E revenue for 37% top-line growth with a defensible first-mover regulatory moat. Versus Natera at 21x for 28% growth, that's a favorable setup. We rate GH a BUY with a $160 price target. Preferred entry: $110–$115 on any near-term technical pullback. Next major catalyst: July 30 Q2 earnings.
DISCLAIMER: This analysis is generated using publicly available data from SEC filings (EDGAR), TipRanks, and FRED. For informational purposes only. Not investment advice. Financial forecasts are model estimates subject to material uncertainty. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions. · May 30, 2026.